Seaside Therapeutics
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Seaside Therapeutics sits in the top decile of US sponsors by registered trial count (#1,137 of 15,751 sponsors by registered trial count).
Seaside Therapeutics: 12 sponsored US clinical trials, none currently recruiting.
Seaside Therapeutics sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 4 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Fragile X Syndrome, with 1 trials.
Top-decile sponsor footprint
Seaside Therapeutics ranks in the top decile of sponsors by registered trial count (#1,137 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Indexed trials (enrollment closed)
12 total, page 1 of 1
An Open Label Extension Study in Subjects With Fragile X Syndrome
NCT01555333
Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
NCT01706523
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
NCT01325220
Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome
NCT01282268
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
NCT01288716
An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders
NCT01064973
An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome
NCT01013480
A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107
NCT00965432
Biomarker and DNA Collection in Subjects Participating in Protocol 22003
NCT00892580
Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders
NCT00846547
Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001
NCT00823368
Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome
NCT00788073
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 5 |
| Phase 3 | 4 |
Therapeutic Areas
How the Seaside Therapeutics archive is shaped
12 indexed studies, none listed as recruiting (0% open); 8 completed (67%).
Phase mix: 4 late (III/IV) vs 6 early (I/II) (balanced across stages).
Top condition: Fragile X Syndrome (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.